Navigation Links
Results of Two Phase 3 CAPACITY Studies of Pirfenidone in IPF Presented at American Thoracic Society (ATS)
Date:5/19/2009

ally significant and clinically meaningful effect on both the primary endpoint of change in percent predicted FVC and secondary endpoints of progression-free survival and categorical change in percent predicted FVC. While CAPACITY 1 did not achieve statistical significance on the primary endpoint, the results were generally consistent with and supportive of CAPACITY 2. Further, the treatment effect observed in the CAPACITY studies was generally consistent with that observed in the Phase 3 study of pirfenidone in IPF patients conducted by Shionogi & Co. Ltd. in Japan."

Dr. Roland du Bois, Professor of Medicine at National Jewish Health, Denver, Colo., and CAPACITY co-chair also commented on the CAPACITY results. "When taken in the context of the urgent unmet medical need for new medicines to treat IPF patients, the collective efficacy and safety data from the two CAPACITY studies, corroborated by a similar study in Japan, make a case for the use of pirfenidone in this disease setting."

Primary Efficacy Endpoint Results

The primary endpoint of both CAPACITY studies was change in percent predicted Forced Vital Capacity (FVC) after 72 weeks of treatment, evaluated with a nonparametric rank ANCOVA. In the CAPACITY 2 study, the primary endpoint was met (p=0.001). In CAPACITY 1, the primary endpoint was not met (p=0.501). An exploratory analysis of pooled primary endpoint data from both studies using the pre-specified primary endpoint test statistic from a nonparametric rank ANCOVA resulted in a P value of 0.005.

A pre-specified repeated measures analysis of the primary endpoint was used to obtain a least squares mean estimate (LS mean) of the magnitude of the treatment effect. The LS mean change in percent predicted FVC at Week 72 was -6.5% and -9.6% in the pirfenidone and placebo groups, respectively, in CAPACITY 2, and -6.5% and -7.2%, respectively, in CAPACITY 1. This represents
'/>"/>

SOURCE InterMune, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related medicine technology :

1. Shire Announces Study Results of the Effects of INTUNIV(TM) (Guanfacine) Extended Release on Secondary Measures in Children with ADHD and Oppositional Symptoms
2. Optimer Pharmaceuticals Presents Results From Fidaxomicin Phase 3 Study for the Treatment of Clostridium difficile Infection
3. BioVex to Report Phase I/II Clinical Trial Results for the Front Line Treatment of Head and Neck Cancer With OncoVEX GM-CSF at the 2009 American Society of Clinical Oncology Meeting
4. TYRX Presents Early Clinical Results from AIGISRX(TM) Antibacterial Envelope Retrospective Registry
5. Metabolic Solutions Development Company Announces Preliminary Results from Phase IIa Clinical Trial
6. AlphaVax Announces Promising Results in Melanoma Studies
7. Ongoing Landmark ROADMAP Study Demonstrates Significant Improvement in Blood Pressure Control at One Year, According to Blinded Results
8. BioCryst Provides Peramivir Update and Reports First Quarter 2009 Financial Results
9. Bionovo Announces First Quarter 2009 Highlights and Financial Results
10. Alexza Reports 2009 First Quarter Financial Results and Updates Clinical Pipeline Status
11. ADVENTRX Announces Results From ANX-514 Bioequivalence Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/1/2014)...  PTC Therapeutics, Inc. (NASDAQ: PTCT ) ... non-statutory stock options to purchase an aggregate of 67,700 ... The awards were made pursuant to the NASDAQ inducement ... employment compensation. The inducement grants were approved ... are being made as an inducement material to each ...
(Date:8/1/2014)... 2014  With monumental health reform coming into effect, ... language. Clinical efficacy is no longer the sole driver ... like PCORI are directing roughly $1 billion a year ... and environments, the federal healthcare ecosystem is changing, and ... outcomes and managed markets to the right people in ...
(Date:8/1/2014)... LAVAL, Quebec and NEW YORK ... Inc. (NYSE/TSX: VRX) and Pershing Square Capital Management, L.P. ... by Allergan, Inc. (NYSE: AGN ) in ... Pershing Square regarding the tender offer rules.  ... an attempt to interfere with shareholders, efforts to call ...
Breaking Medicine Technology:PTC Therapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) 2Pharmaceuticals Learning the Language of the New Healthcare Landscape 2Pharmaceuticals Learning the Language of the New Healthcare Landscape 3Valeant Pharmaceuticals And Pershing Square Respond To Frivolous Allergan Lawsuit 2Valeant Pharmaceuticals And Pershing Square Respond To Frivolous Allergan Lawsuit 3Valeant Pharmaceuticals And Pershing Square Respond To Frivolous Allergan Lawsuit 4Valeant Pharmaceuticals And Pershing Square Respond To Frivolous Allergan Lawsuit 5Valeant Pharmaceuticals And Pershing Square Respond To Frivolous Allergan Lawsuit 6
... 15 Dynatronics Corporation (Nasdaq: DYNT ) today announced ... from Nasdaq stating that the Company has not complied with ... , Nasdaq provides the Company an opportunity to appeal this ... authorized to grant up to 180 additional calendar days to ...
... Verathon Inc. is pleased to introduce the GlideScope(®) ... views in DVD clarity, enabling quick intubation. The ... and digital camera, offers integrated real-time recording as well ... This latest addition to the GlideScope(®) brand also provides ...
Cached Medicine Technology:Verathon Introduces the GlideScope(R) Cobalt Advanced Video Laryngoscope (AVL); New Digital Technology Facilitates Quick Intubations 2
(Date:8/1/2014)... August 02, 2014 The successful development ... stamping business of Guangdong FODAY Automobile Co.,LTD. As early ... company had already organized an excellent team to develop ... of detailed, in-depth technical plans. The company’s vice president ... in the direct involvement of the specific arrangement and ...
(Date:8/1/2014)... one of the most famous dress suppliers in the world, ... online. At the moment, all the brand new items ... to the company’s senior spokesman, the special offer will last ... is limited. Those who are thinking of buying cheap bridesmaid ... All its products are delicately made by top designers. ...
(Date:8/1/2014)... Cannabis use among young people has spiked, with ... used marijuana at least once and 17 percent admitting to ... Drugs, Say ‘Yes to Life,’ volunteers from the Church of ... with factual information about drugs, to help reverse this alarming ... to Drugs, Say ‘Yes’ to Life,” volunteers have distributed 40,000 ...
(Date:8/1/2014)... The Judicial Panel on Multidistrict Litigation ... therapy caused strokes, heart attacks, and other injuries in ... F. Kennelly as the transferee judge and ordered what ... federal court. , As one of his first organizing ... of attorneys who will move the litigation forward on ...
(Date:8/1/2014)... Diego School of Medicine report that dietary capsaicin ... activation of a receptor on cells lining the intestines ... risk of colorectal tumors. , The findings are published ... Journal of Clinical Investigation . , The receptor or ... neurons, where it acts as a sentinel for heat, ...
Breaking Medicine News(10 mins):Health News:FODAY Automobile Company Is Now Working On The C60F FODAY Project 2Health News:iFitDress.com: Top Bridesmaid Dresses For The Global Customers 2Health News:Addressing a Serious Issue Affecting German Teens 2Health News:Judge Kennelly Appoints Attorney Michelle Kranz to the Plaintiffs’ Executive Committee in the Testosterone Replacement Therapy MDL 2Health News:Pepper and halt: Spicy chemical may inhibit gut tumors 2
... over 100 NFL Legends Announced, TAMPA, Fla., ... (GGAF) today announced an unprecedented humanitarian,initiative to assist ... U.S. Military Special Operations personnel and their families,through ... partnership today and unveiled a Gridiron Greats Super ...
... Mickey,s accidental death (October 18th) Hunter has been,changing ... Outreach,Foundation as National Spokesperson., CHICAGO, Nov. 12 ... Epilepsy Outreach Foundation (AEOF),joins with Hunter Tylo of ... nationwide,campaign to raise awareness of Epilepsy and educate ...
... accuracy of their annual formulations for human influenza vaccines ... the time, especially for seniors. Perhaps in part because ... upcoming influenza strains, approximately 36,000 people die each year ... the case of hurricanes, early warning of the location ...
... Nov. 12 As the exclusive official,breaking news service ... PR Newswire is featuring profiles of the exhibiting,organizations. The ... Company : Linemaster Switch ... Web URL : ...
... to ... reduces errors and hospital costs, DAYTONA BEACH, ... medication error reduction and hospital pharmacy I.V.,room automation, recently ... IntelliFill i.v.(TM), by the Alegent Health System. The,largest not-for-profit, ...
... Increased use of computers to create predictive models ... organised by the European Science Foundation (ESF), which ... the field. Human disease research produces an enormous ... animal models, high throughput genetic screening of human ...
Cached Medicine News:Health News:Warriors Unite: Mike Ditka & the Gridiron Greats Form Partnership to Assist Retired NFL Players & U.S. Military Special Operations Personnel 2Health News:Warriors Unite: Mike Ditka & the Gridiron Greats Form Partnership to Assist Retired NFL Players & U.S. Military Special Operations Personnel 3Health News:November: National Epilepsy Awareness Month Actress Hunter Tylo Turns Tragic Loss Into Hope 2Health News:A New Way to Predict Outbreaks: Replikin Peptide Concentration in H5N1 Influenza Virus Genome as a Marker for Lethal Outbreaks 2Health News:A New Way to Predict Outbreaks: Replikin Peptide Concentration in H5N1 Influenza Virus Genome as a Marker for Lethal Outbreaks 3Health News:A New Way to Predict Outbreaks: Replikin Peptide Concentration in H5N1 Influenza Virus Genome as a Marker for Lethal Outbreaks 4Health News:Linemaster Switch Corporation Exhibiting at MEDICA 2008 2Health News:Alegent Health System Automates I.V. Preparation to Enhance Patient Safety 2Health News:Computers make sense of experiments on human disease 2Health News:Computers make sense of experiments on human disease 3
... Proven tension-free sling technology ... porcine acellular collagen matrix sling, ... tissue-to-tissue contact between sling and ... urethral or vaginal abrasion or ...
... Delivers the advanced performance ... exceptional strength, versatility, and durability ... implant that augments the effectiveness ... pelvic floor reconstruction. Comprised of ...
... system is a state-of-the-art, comprehensive cardiac ... programs, modalities, and parameters are highly ... multiple applications including cardiac and pulmonary ... clinics. Its open architecture delivers flexibility ...
NephroMax High Pressure Nephrostomy Balloon Catheter allows one-step, atraumatic dilatation of the nephrostomy tract....
Medicine Products: